All-oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: The ALLY-3+ phase 3 study

Authors
Category Primary study
ConferenceHepatology
Year 2015
This article has no abstract
Epistemonikos ID: c2fa114296a7c2b87b036dcdb473819c2d753e36
First added on: Apr 29, 2026